Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database
- 1 June 1999
- journal article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 14 (6) , 1500-1505
- https://doi.org/10.1093/humrep/14.6.1500
Abstract
In October 1995 the Committee on Safety of Medicines advised UK doctors and pharmacists that oral contraceptives containing desogestrel and gestodene were associated with double the risk of venous thromboembolic events (VTE) compared to pills containing other progestogens. In 1997 data was analysed from the MediPlus database of UK general practitioner records, which reported odds ratios for desogestrel and gestodene lower than that for levonorgestrel. Here the results of a more stringent nested case control analysis on the MediPlus database are reported. The study was larger and cases were verified. A crude incidence of idiopathic VTE was found amongst users of combined oral contraceptives of 4.6 per 10 000 exposed women years. Using levonorgestrel 150 microg + ethinyloestradiol 30 microg as reference, non-significant odds ratios of 1.1 (0.5-2.6) for desogestrel 150 microg + ethinyloestradiol 30 microg and 1.1 (0.5-2.4) for gestodene 75 microg + ethinyloestradiol 30 microg were found. The results of this study show no significant difference in risk between different formulations of combined oral contraceptive.Keywords
This publication has 11 references indexed in Scilit:
- Combined oral contraceptives, smoking, and cardiovascular riskJournal of Epidemiology and Community Health, 1998
- Third-generation oral contraceptives and venous thrombosisThe Lancet, 1997
- Third-generation oral contraceptives and venous thrombosisThe Lancet, 1997
- Third-generation oral contraceptives and venous thrombosisThe Lancet, 1997
- Population-based study of risk of venous thromboembolism associated with various oral contraceptivesThe Lancet, 1997
- The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational researchContraception, 1996
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Oral Contraceptive Oestrogen and Progestin Potencies and the Incidence of Deep Venous ThromboembolismInternational Journal of Epidemiology, 1990